logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 4 of 4 Items
Showing 1 - 4 of 4 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine

Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C,  et al.
2014-07-21 • American Journal of Tropical Medicine and Hygiene
2014-07-21 • American Journal of Tropical Medicine and Hygiene
Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the artemisinin component and the partner drug. Polymorphisms in the Plasmodium falciparum chloroq...
Journal Article
|
Research

Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis

Kloprogge F, Workman L, Borrmann S, Tekete M, Lefevre G,  et al.
2018-06-12 • PLOS Medicine
2018-06-12 • PLOS Medicine
The fixed dose combination of artemether-lumefantrine (AL) is the most widely used treatment for uncomplicated Plasmodium falciparum malaria. Relatively lower cure rates and lumefantrine...
Journal Article
|
Research

Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis

WorldWide Antimalarial Resistance Network Methodology Study Group, Dahal P, Simpson JA, Abdulla S, Achan J,  et al.
2019-07-05 • Malaria Journal
2019-07-05 • Malaria Journal
BACKGROUND
Therapeutic efficacy studies in uncomplicated Plasmodium falciparum malaria are confounded by new infections, which constitute competing risk events since they can potenti...
Journal Article
|
Research

Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial

Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S,  et al.
2009-11-17 • PLOS One
2009-11-17 • PLOS One
BACKGROUND: Artemisinin combination therapies (ACTs) are currently the preferred option for treating uncomplicated malaria. Dihydroartemisinin-piperaquine (DHA-PQP) is a promising fixed-...